|
1
|
Huizinga JD, Thuneberg L, Klüppel M,
Malysz J, Mikkelsen HB and Bernstein A: W/kit gene required for
interstitial cells of Cajal and for intestinal pacemaker activity.
Nature. 373:347–349. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamamoto H and Oda Y: Gastrointestinal
stromal tumor: Recent advances in pathology and genetics. Pathol
Int. 65:9–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeMatteo RP, Lewis JJ, Leung D, Mudan SS,
Woodruff JM and Brennan MF: Two hundred gastrointestinal stromal
tumors: Recurrence patterns and prognostic factors for survival.
Ann Surg. 231:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi S, Miceli R, Messerini L, Bearzi I,
Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A,
Toffolatti L, et al: Natural history of imatinib-naive GISTs: A
retrospective analysis of 929 cases with long-term follow-up and
development of a survival nomogram based on mitotic index and size
as continuous variables. Am J Surg Pathol. 35:1646–1456. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joensuu H: Risk stratification of patients
diagnosed with gastrointestinal stromal tumor. Hum Pathol.
39:1411–1419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y,
He Y, Liang X, Liu X, Zhou Y, et al: Chinese consensus guidelines
for diagnosis and management of gastrointestinal stromal tumor.
Chin J Cancer Res. 29:281–293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goh BK, Chow PK, Yap WM, Kesavan SM, Song
IC, Paul PG, Ooi BS, Chung YF and Wong WK: Which is the optimal
risk stratification system for surgically treated localized primary
GIST? Comparison of three contemporary prognostic criteria in 171
tumors and a proposal for a modified Armed Forces Institute of
Pathology risk criteria. Ann Surg Oncol. 15:2153–2163. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lokuhetty D, White VA and Watanabe R: WHO
classfication of digestive system tumours. 5th edition. Lyon: IARC
Press; pp. 439–443. 2019
|
|
10
|
Wozniak A, Rutkowski P, Piskorz A,
Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk
K, et al: Prognostic value of KIT/PDGFRA mutations in
gastrointestinal stromal tumours (GIST): Polish Clinical GIST
Registry experience. Ann Oncol. 23:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wozniak A, Rutkowski P, Schöffski P,
Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E,
Limon J, Blay JY, et al: Tumor genotype is an independent
prognostic factor in primary gastrointestinal stromal tumors of
gastric origin: A european multicenter analysis based on
ConticaGIST. Clin Cancer Res. 20:6105–6116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corless CL, Ballman KV, Antonescu CR,
Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD,
Demetri GD, Heinrich MC, et al: Pathologic and molecular features
correlate with long-term outcome after adjuvant therapy of resected
primary GI stromal tumor: The ACOSOG Z9001 trial. J Clin Oncol.
32:1563–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heinrich MC, Owzar K, Corless CL, Hollis
D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin
C, et al: Correlation of kinase genotype and clinical outcome in
the North American intergroup phase III Trial of imatinib mesylate
for treatment of advanced gastrointestinal stromal tumor: CALGB
150105 study by cancer and leukemia group B and southwest oncology
group. J Clin Oncol. 26:5360–5367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szucs Z, Thway K, Fisher C, Bulusu R,
Constantinidou A, Benson C, van der Graaf WT and Jones RL:
Molecular subtypes of gastrointestinal stromal tumors and their
prognostic and therapeutic implications. Future Oncol. 13:93–107.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lennartsson J, Jelacic T, Linnekin D and
Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine
kinase kit. Stem Cells. 23:16–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martin-Broto J, Gutierrez A,
Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande
LM, Lainez N, Maurel J, De Juan A, Losa F, et al: Prognostic time
dependence of deletions affecting codons 557 and/or 558 of KIT gene
for relapse-free survival (RFS) in localized GIST: A Spanish group
for sarcoma research (GEIS) study. Ann Oncol. 21:1552–1557. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martín J, Poveda A, Llombart-Bosch A,
Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig
S, Gutierrez A, González de Sande JL, et al: Deletions affecting
codons 557–558 of the c-KIT gene indicate a poor prognosis in
patients with completely resected gastrointestinal stromal tumors:
A study by the Spanish group for sarcoma research (GEIS). J Clin
Oncol. 23:6190–6198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steigen SE, Eide TJ, Wasag B, Lasota J,
Lasota J and Miettinen M: Mutations in gastrointestinal stromal
tumors-a population-based study from Northern Norway. APMIS.
115:289–298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gill AJ: Succinate dehydrogenase (SDH) and
mitochondrial driven neoplasia. Pathology. 44:285–292. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miettinen M, Wang ZF, Sarlomo-Rikala M,
Osuch C, Rutkowski P and Lasota J: Succinate
dehydrogenase-deficient GISTs: A clinicopathologic,
immunohistochemical, and molecular genetic study of 66 gastric
GISTs with predilection to young age. Am J Surg Pathol.
35:1712–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He HY, Fang WG, Zhong HH, Li Y, Zheng J,
Du J, Heng WJ and Wu BQ: Status and clinical implication of c-kit
and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor
(GIST). Zhonghua Bing Li Xue Za Zhi. 35:262–266. 2006.(In Chinese).
PubMed/NCBI
|
|
22
|
Du CY, Shi YQ, Zhou Y, Fu H and Zhao G:
The analysis of status and clinical implication of KIT and PDGFRA
mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol.
98:175–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hashmi AA, Faraz M, Nauman Z, Qureshi MU,
Hashmi SK, Waseem HF, Edhi MM, Faridi N and Khan A:
Clinicopathologic features and prognostic grouping of
gastrointestinal stromal tumors (GISTs) in Pakistani patients: An
institutional perspective. BMC Res Notes. 11:4572018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mayr P, Märkl B, Agaimy A, Kriening B,
Dintner S, Schenkirsch G and Schneider-Stock R: Malignancies
associated with GIST: A retrospective study with molecular analysis
of KIT and PDGFRA. Langenbecks Arch Surg. 404:605–613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Qiu H, Zhang P, Feng X, Chen T, Li
Y, Tao K, Li G, Sun X and Zhou Z; China Gastrointestinal Stromal
Tumor Study Group (CN-GIST), : Prognostic role of tumor necrosis in
patients undergoing curative resection for gastric gastrointestinal
stromal tumor: A multicenter analysis of 740 cases in China. Cancer
Med. 6:2796–2803. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu FY, Qi JP, Xu FL and Wu AP:
Clinicopathological and immunohistochemical analysis of
gastrointestinal stromal tumor. World J Gastroenterol.
12:4161–4165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Debiec-Rychter M, Sciot R, Le Cesne A,
Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S,
Stul M, Casali PG, et al: KIT mutations and dose selection for
imatinib in patients with advanced gastrointestinal stromal
tumours. Eur J Cancer. 42:1093–1103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M, Xu J, Zhao W, Tu L, Qiu W, Wang C,
Shen Y, Liu Q and Cao H: Prognostic value of mutational
characteristics in gastrointestinal stromal tumors: A single-center
experience in 275 cases. Med Oncol. 31:8192014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wardelmann E, Losen I, Hans V, Neidt I,
Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R and
Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the
juxtamembrane domain of the c-kit protooncogene is associated with
metastatic behavior of gastrointestinal stromal tumors. Int J
Cancer. 106:887–895. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Capelli L, Petracci E, Quagliuolo V,
Saragoni L, Colombo P, Morgagni P, Calistri D, Tomezzoli A, Di
Cosmo M, Roviello F, et al: Gastric GISTs: Analysis of c-Kit,
PDGFRA and BRAF mutations in relation to prognosis and clinical
pathological characteristics of patients-A GIRCG study. Eur J Surg
Oncol. 42:1206–1214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Antonescu CR, Romeo S, Zhang L, Nafa K,
Hornick JL, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei
Tos PA and Fletcher CD: Dedifferentiation in gastrointestinal
stromal tumor to an anaplastic KIT-negative phenotype: A diagnostic
pitfall: Morphologic and molecular characterization of 8 cases
occurring either de novo or after imatinib therapy. Am J Surg
Pathol. 37:385–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liegl B, Kepten I, Le C, Zhu M, Demetri
GD, Heinrich MC, Fletcher CD, Corless CL and Fletcher JA:
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J
Pathol. 216:64–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Serrano C, Mariño-Enríquez A, Tao DL,
Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD,
et al: Complementary activity of tyrosine kinase inhibitors against
secondary kit mutations in imatinib-resistant gastrointestinal
stromal tumours. Br J Cancer. 120:612–620. 2019. View Article : Google Scholar : PubMed/NCBI
|
